Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Current Liabilities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Total Current Liabilities for 16 consecutive years, with $21.9 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 6.0% to $21.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.9 million through Dec 2025, down 6.0% year-over-year, with the annual reading at $21.9 million for FY2025, 6.0% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $21.9 million at Anika Therapeutics, up from $19.1 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $47.0 million in Q1 2021, with the low at $16.1 million in Q2 2025.
  • Average Total Current Liabilities over 5 years is $27.4 million, with a median of $27.5 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities skyrocketed 79.37% in 2021, then tumbled 42.54% in 2022.
  • Over 5 years, Total Current Liabilities stood at $29.8 million in 2021, then decreased by 6.31% to $27.9 million in 2022, then grew by 11.27% to $31.1 million in 2023, then decreased by 24.96% to $23.3 million in 2024, then dropped by 6.0% to $21.9 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $21.9 million, $19.1 million, and $16.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.